CVE:NXG

NexgenRx Stock Forecast, Price & News

C$0.34

-0.01 (-1.45 %)

(As of 09/15/2021 10:38 AM ET)

Add

Compare

Today's Range

C$0.34

▼

C$0.35

50-Day Range

C$0.33

▼

C$0.45

52-Week Range

C$0.14

▼

C$0.60

Volume225,000 shs

Average Volume32,932 shs

Market CapitalizationC$23.91 million

P/E Ratio12.14

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive NXG News and Ratings via Email

Sign-up to receive the latest news and ratings for NexgenRx and its competitors with MarketBeat's FREE daily newsletter.

About NexgenRx

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. It offers prescription drug claims; dental claims; and claims for extended health benefits, as well as provides a health care spending account that offers an amount of money to an individual to pay for health or dental benefits. The company also provides individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; direct deposit services; and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.

I Ran A Stock Scan For Earnings Growth And NexgenRx (CVE:NXG) Passed With Ease
August 20, 2021 | finance.yahoo.com

NexgenRx Inc.: NexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDA
August 18, 2021 | finanznachrichten.de

NexgenRx Inc.: NexgenRx Announces Financial Results for Q1 2021 with Continued EBITDA and Net Profit Growth
May 27, 2021 | finanznachrichten.de

NexgenRx Announces 2020 Year End Results with Record EBITDA and Net Profit
March 31, 2021 | finance.yahoo.com

NXG.V - NexgenRx Inc. Profile | Reuters
February 2, 2021 | reuters.com

How Is NexgenRx's (CVE:NXG) CEO Paid Relative To Peers?
August 25, 2020 | finance.yahoo.com

NexgenRx Inc.: NexgenRx Announces 2020 Q2 Interim Results
August 20, 2020 | finanznachrichten.de

NexgenRx Announces 2020 Q2 Interim Results
August 20, 2020 | benzinga.com

NexgenRX Inc.
June 21, 2020 | www.barrons.com

NexgenRx Announces 2020 Q1 Interim Results
May 11, 2020 | www.baystreet.ca

See More Headlines

Industry, Sector and Symbol

Stock Exchange CVE
Industry Health Care Plans
Sub-IndustryN/A
SectorMedical
Current SymbolCVE:NXG
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.nexgenrx.com
Phone+1-416-6953393
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesC$10.86 million
Price / Sales2.20
Cash FlowC$0.01 per share
Price / Cash Flow31.36
Book ValueC$0.07 per share
Price / Book5.00

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares70,336,000
Market CapC$23.91 million
Next Earnings Date11/18/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for NexgenRx.

4.1 Community Rank

Outperform Votes
NexgenRx has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NexgenRx has received 34 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NexgenRx has received 61.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NexgenRx and other stocks. Vote “Outperform” if you believe NXG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NXG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
NexgenRx does not currently pay a dividend.
Dividend Growth
NexgenRx does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NexgenRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$14,665.00 in company stock and sold C$0.00 in company stock.

1.3 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of NexgenRx is 12.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 14.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of NexgenRx is 12.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.99.
Price to Book Value per Share Ratio
NexgenRx has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

NexgenRx (CVE:NXG) Frequently Asked Questions

What stocks does MarketBeat like better than NexgenRx?

Wall Street analysts have given NexgenRx a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NexgenRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NexgenRx's next earnings date?

NexgenRx is scheduled to release its next quarterly earnings announcement on Thursday, November 18th 2021.
View our earnings forecast for NexgenRx.

How has NexgenRx's stock price been impacted by Coronavirus (COVID-19)?

NexgenRx's stock was trading at C$0.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NXG stock has increased by 88.9% and is now trading at C$0.34.
View which stocks have been most impacted by COVID-19.

Who are NexgenRx's key executives?

NexgenRx's management team includes the following people:

Mr. Ronald C. Loucks, Founder, CEO, Pres & Director (Age 71, Pay $152.58k)
Mr. Kelly Ehler CPA, CA, Chief Financial Officer
Mr. Hugh C. Hart, VP of Sales & Account Management
Mr. Andrew Munroe, Director of Operations
Ms. Margaret Ingram, Pharmacist Consultant

Who are some of NexgenRx's key competitors?

Some companies that are related to NexgenRx include MediWound (MDWD), Diaceutics (DXRX), BioSyent (RX), Pluristem Therapeutics (PSTI), Aziyo Biologics (AZYO), Medigene (MDG1), AIM ImmunoTech (AIM), SkinBioTherapeutics (SBTX), Neptune Wellness Solutions (NEPT), Isoray (ISR), Shineco (TYHT), Lumos Pharma (LUMO), Pro-Dex (PDEX), RenovaCare (RCAR) and Otonomy (OTIC).
View all of NXG's competitors.

What other stocks do shareholders of NexgenRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NexgenRx investors own include WestJet Airlines (WJA) and Hydro One (H).

What is NexgenRx's stock symbol?

NexgenRx trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NXG."

How do I buy shares of NexgenRx?

Shares of NXG and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is NexgenRx's stock price today?

One share of NXG stock can currently be purchased for approximately C$0.34.

How much money does NexgenRx make?

NexgenRx has a market capitalization of C$23.91 million and generates C$10.86 million in revenue each year.

What is NexgenRx's official website?

The official website for NexgenRx is www.nexgenrx.com.

Where are NexgenRx's headquarters?

NexgenRx is headquartered at 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada.

How can I contact NexgenRx?

NexgenRx's mailing address is 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada. The company can be reached via phone at +1-416-6953393.

This page was last updated on 9/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NexgenRx Stock Forecast, Price & News

About NexgenRx

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

4.1 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth